Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/54356
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPicornell, A. C.-
dc.contributor.authorEchavarria, I.-
dc.contributor.authorAlvarez, E.-
dc.contributor.authorLópez-Tarruella, S.-
dc.contributor.authorJerez, Y.-
dc.contributor.authorHoadley, K.-
dc.contributor.authorParker, J. S.-
dc.contributor.authordel Monte-Millán, M.-
dc.contributor.authorRamos-Medina, R.-
dc.contributor.authorGayarre, J.-
dc.contributor.authorOcaña, I.-
dc.contributor.authorCebollero, M.-
dc.contributor.authorMassarrah, T.-
dc.contributor.authorMoreno, F.-
dc.contributor.authorGarcía Saenz, J. A.-
dc.contributor.authorGómez Moreno, H.-
dc.contributor.authorBallesteros, A.-
dc.contributor.authorRuiz Borrego, M.-
dc.contributor.authorPerou, C. M.-
dc.contributor.authorMartin, M.-
dc.date.accessioned2021-04-30T10:50:21Z-
dc.date.available2021-04-30T10:50:21Z-
dc.date.issued2019-06-03-
dc.identifier.citationBreast cancer PAM50 signature: correlation and concordance between RNA-Seq and digital multiplexed gene expression technologies in a triple negative breast cancer serieses_ES
dc.identifier.issn1471-2164-
dc.identifier.urihttps://hdl.handle.net/20.500.12530/54356-
dc.description.abstractFull RNA-Seq is a fundamental research tool for whole transcriptome analysis. However, it is too costly and time consuming to be used in routine clinical practice. We evaluated the transcript quantification agreement between RNA-Seq and a digital multiplexed gene expression platform, and the subtype call after running the PAM50 assay in a series of breast cancer patients classified as triple negative by IHC/FISH. The goal of this study is to analyze the concordance between both expression platforms overall, and for calling PAM50 triple negative breast cancer intrinsic subtypes in particular.es_ES
dc.language.isoenes_ES
dc.publisherBioMed Centrales_ES
dc.relation.isversionofPublisher's versiones_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/publicdomain/zero/1.0/*
dc.subjectTriple Negative Breast Canceres_ES
dc.subjectRNA-Seqes_ES
dc.subjectNanoStringes_ES
dc.subject.meshBiomarkers, Tumor / genetics*es_ES
dc.subject.meshGene Expression Profiling / methods*es_ES
dc.subject.meshHigh-Throughput Nucleotide Sequencing / methods*es_ES
dc.subject.meshNeoplasm Recurrence, Locales_ES
dc.subject.meshTriple Negative Breast Neoplasmses_ES
dc.titleBreast cancer PAM50 signature: correlation and concordance between RNA-Seq and digital multiplexed gene expression technologies in a triple negative breast cancer serieses_ES
dc.typeArtículoes_ES
dc.identifier.pubmedID31159741es_ES
dc.format.volume20es_ES
dc.format.page452es_ES
dc.description.peerreviewedes_ES
dc.identifier.journalBMC Genomicses_ES
dc.identifier.journalabbreviationBMC Genomicses_ES
dc.contributor.authoraffiliationInstituto de Investigación Sanitaria Gregorio Marañónes_ES
dc.format.number1es_ES
Appears in Collections:Hospitales > H. U. Gregorio Marañón > Artículos

Files in This Item:
File Description SizeFormat 
s12864-019-5849-0.pdf1,83 MBAdobe PDFThumbnail
View/Open


This item is licensed under a Creative Commons License Creative Commons